Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence of definite antiphospholipid syndrome in carriers of the JAK2V617F mutation.

Thrombosis research - 1 Feb 2021

Janjetovic Snjezana, Beckmann Lennart, Holstein Katharina, Rolling Christina, Thiele Benjamin, Schafhausen Philippe, Schön Gerhard, Bokemeyer Carsten, Langer Florian, Voigtlaender Minna

Abstract excerpt

INTRODUCTION: Patients with Philadelphia-negative myeloproliferative neoplasms (MPNs), particularly those carrying the JAK2V617F mutation, are at increased risk of thrombosis. While an association of MPNs with autoimmune disorders has been established, the prevalence of inherited or acquired thrombophilias in JAK2V617F-positive patients remains obscure. We therefore investigated the coincidence of the JAK2V617F...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiphospholipid Syndrome
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myeloproliferative Disorders

Share to Prevalence

Source

Identifiers

PMID: 33290883
DOI: 10.1016/j.thromres.2020.11.027

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence of definite antiphospholipid syndrome in carriers of the JAK2V617F mutation.PMID 33290883Read ↗

Association of JAK2V617F mutation with thrombosis in Indian patients with Philadelphia negative chronic myeloproliferative neoplasms.Semantic proximity Read ↗

Association between JAK2V617F variable allele frequency and risk of thrombotic events in patients with myeloproliferative neoplasmsSemantic proximity Read ↗

The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.Semantic proximity Read ↗

Features of immune mediated diseases in JAK2 (V617F)-positive myeloproliferative neoplasms and the potential therapeutic role of JAK inhibitors.Semantic proximity Read ↗

JAK2 allele burden is correlated with a risk of venous but not arterial thrombosis.Semantic proximity Read ↗

The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.Semantic proximity Read ↗

[The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].Semantic proximity Read ↗

[The frequency of JAK2 V617F mutation, expression level of phosphorylated JAK/STATs proteins and their clinical significance in myeloproliferative disorders patients].Semantic proximity Read ↗

JAK2 mutation and thrombosis in the myeloproliferative neoplasms.Semantic proximity Read ↗

[Analysis of risk factors for thromboembolism in patients with JAK2V617F gene mutation positive myeloproliferative neoplasms].Semantic proximity Read ↗

No Differences in Outcomes Between JAK2 V617F-Positive Patients with Variant Allele Fraction < 2% Versus 2-10%: A 6-Year Province-wide Retrospective Analysis.Semantic proximity Read ↗

The impact of JAK2V617F mutation on Philadelphia-negative myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.